1/20/2024 0 Comments Risky stocks to buy now![]() The company has been using the drug's sales to fund additional trials to possibly expand its commercial opportunity by perhaps another $1 billion annually. Harmony Biosciences hasn't been sitting still, however. Food and Drug Administration (FDA)-approved narcolepsy medication, Wakix (pitolisant), has been capturing market share at a breakneck pace since hitting its commercial launch, and it is potentially on track to eclipse the $1 billion sales mark well before the end of the decade in this setting. Harmony Biosciences is a rare neurological disease specialist. Harmony Biosciences: A multi-catalyst pharma play Hence, this low-priced biotech stock screens as an attractive buy-and-hold for folks with an extended investing horizon. But the overall trend for its core value drivers ought to be upward over the next 10 to 20 years. Ginkgo Bioworks does have some unique risk factors as a pioneer in the emerging industrial biotechnology space. Speaking to this point, its cell engineering and biosecurity units have already attracted multiple partners with deep pockets, and both of these sub-industries are expected to grow at a rapid clip in the years ahead. The bottom line is that Ginkgo Bioworks is building a novel bio business capable of generating billions in annual revenue. ![]() In stark contrast, the company has actually been steadily building a world-class portfolio of clients, improving its facilities to attract additional clients, and garnering the attention of all-star investors like Cathie Wood. None of these negative headwinds reflect Ginkgo Bioworks' progress over the prior two years, however. The biotech's falling share price over this period is the result of several factors, such as the 2022 bear market that pummeled growth-oriented equities at large, a marked shift away from cash flow negative companies by investors over this period, and the apparent evaporation of "deep value" from the market's lexicon. What's the investing thesis? Since its IPO a little over two years ago, Ginkgo Bioworks stock has slumped by an unsightly 83%. Its impressive client roster includes industry titans such as Alphabet (via Google Cloud), Merck, Pfizer, and Novo Nordisk. Ginkgo Bioworks earns money through collaboration and manufacturing deals with private clients and government agencies in the U.S. The company's research, development, and manufacturing services cover a wide variety of areas such as agriculture, drug discovery, industrial manufacturing, and, of course, biosecurity. ![]() It reports earnings via two segments: Cell Engineering and Biosecurity. Ginkgo Bioworks is an industrial biotechnology company. Ginkgo Bioworks: An underappreciated biotech ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |